Levosulpiride‐induced movement disorders
Identifieur interne : 001C86 ( Istex/Corpus ); précédent : 001C85; suivant : 001C87Levosulpiride‐induced movement disorders
Auteurs : Hae-Won Shin ; Mi J. Kim ; Jong S. Kim ; Myoung C. Lee ; Sun J. ChungSource :
- Movement Disorders [ 0885-3185 ] ; 2009-11-15.
English descriptors
Abstract
Levosulpiride is a substituted benzamide that is widely used for the management of dyspepsia and emesis. However, little is known about levosulpiride‐induced movement disorders (LIM). The aim of this study was to investigate the clinical characteristics of patients with LIM. Among 132 consecutive patients who were diagnosed with drug‐induced movement disorders between January 2002 and March 2008, 91 patients with LIM were identified and their medical records reviewed. Seventy‐eight (85.7%) patients were aged more than 60 years. The most common LIM was parkinsonism (LIP) (n = 85, 93.4%), followed by tardive dyskinesia (n = 9, 9.9%) and isolated tremor (n = 3, 3.3%). Twenty‐one (24.7%) of the 85 patients with LIP were rated as Hoehn and Yahr stage III–V. The oro‐lingual area was the only body part that was involved by tardive dyskinesia. LIM persisted after withdrawal of levosulpiride in 48.1% of patients with LIP, 66.7% with dyskinesia, and none with isolated tremor. None of clinical and MRI features predicted the reversibility of LIP. Levosulpiride frequently causes drug‐induced movement disorders, presenting mainly with LIP followed by lower face dyskinesia. The symptoms are often severe, and irreversible even after the withdrawal of levosulpiride. Physicians should be cautious in using levosulpiride, especially in elderly patients. © 2009 Movement Disorder Society
Url:
DOI: 10.1002/mds.22805
Links to Exploration step
ISTEX:0E863B81DEB3FE5A3F083702B586A9FCC29E9D9CLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Levosulpiride‐induced movement disorders</title><author><name sortKey="Shin, Hae On" sort="Shin, Hae On" uniqKey="Shin H" first="Hae-Won" last="Shin">Hae-Won Shin</name><affiliation><mods:affiliation>Parkinson/Alzheimer Center, Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea</mods:affiliation></affiliation></author><author><name sortKey="Kim, Mi J" sort="Kim, Mi J" uniqKey="Kim M" first="Mi J." last="Kim">Mi J. Kim</name><affiliation><mods:affiliation>Parkinson/Alzheimer Center, Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea</mods:affiliation></affiliation></author><author><name sortKey="Kim, Jong S" sort="Kim, Jong S" uniqKey="Kim J" first="Jong S." last="Kim">Jong S. Kim</name><affiliation><mods:affiliation>Parkinson/Alzheimer Center, Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea</mods:affiliation></affiliation></author><author><name sortKey="Lee, Myoung C" sort="Lee, Myoung C" uniqKey="Lee M" first="Myoung C." last="Lee">Myoung C. Lee</name><affiliation><mods:affiliation>Parkinson/Alzheimer Center, Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea</mods:affiliation></affiliation></author><author><name sortKey="Chung, Sun J" sort="Chung, Sun J" uniqKey="Chung S" first="Sun J." last="Chung">Sun J. Chung</name><affiliation><mods:affiliation>Parkinson/Alzheimer Center, Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:0E863B81DEB3FE5A3F083702B586A9FCC29E9D9C</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/mds.22805</idno><idno type="url">https://api.istex.fr/document/0E863B81DEB3FE5A3F083702B586A9FCC29E9D9C/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001C86</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Levosulpiride‐induced movement disorders</title><author><name sortKey="Shin, Hae On" sort="Shin, Hae On" uniqKey="Shin H" first="Hae-Won" last="Shin">Hae-Won Shin</name><affiliation><mods:affiliation>Parkinson/Alzheimer Center, Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea</mods:affiliation></affiliation></author><author><name sortKey="Kim, Mi J" sort="Kim, Mi J" uniqKey="Kim M" first="Mi J." last="Kim">Mi J. Kim</name><affiliation><mods:affiliation>Parkinson/Alzheimer Center, Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea</mods:affiliation></affiliation></author><author><name sortKey="Kim, Jong S" sort="Kim, Jong S" uniqKey="Kim J" first="Jong S." last="Kim">Jong S. Kim</name><affiliation><mods:affiliation>Parkinson/Alzheimer Center, Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea</mods:affiliation></affiliation></author><author><name sortKey="Lee, Myoung C" sort="Lee, Myoung C" uniqKey="Lee M" first="Myoung C." last="Lee">Myoung C. Lee</name><affiliation><mods:affiliation>Parkinson/Alzheimer Center, Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea</mods:affiliation></affiliation></author><author><name sortKey="Chung, Sun J" sort="Chung, Sun J" uniqKey="Chung S" first="Sun J." last="Chung">Sun J. Chung</name><affiliation><mods:affiliation>Parkinson/Alzheimer Center, Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-11-15">2009-11-15</date><biblScope unit="vol">24</biblScope><biblScope unit="issue">15</biblScope><biblScope unit="page" from="2249">2249</biblScope><biblScope unit="page" to="2253">2253</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">0E863B81DEB3FE5A3F083702B586A9FCC29E9D9C</idno><idno type="DOI">10.1002/mds.22805</idno><idno type="ArticleID">MDS22805</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinsonism</term><term>drug‐induced movement disorders</term><term>dyskinesia</term><term>levosulpiride</term><term>tremor</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Levosulpiride is a substituted benzamide that is widely used for the management of dyspepsia and emesis. However, little is known about levosulpiride‐induced movement disorders (LIM). The aim of this study was to investigate the clinical characteristics of patients with LIM. Among 132 consecutive patients who were diagnosed with drug‐induced movement disorders between January 2002 and March 2008, 91 patients with LIM were identified and their medical records reviewed. Seventy‐eight (85.7%) patients were aged more than 60 years. The most common LIM was parkinsonism (LIP) (n = 85, 93.4%), followed by tardive dyskinesia (n = 9, 9.9%) and isolated tremor (n = 3, 3.3%). Twenty‐one (24.7%) of the 85 patients with LIP were rated as Hoehn and Yahr stage III–V. The oro‐lingual area was the only body part that was involved by tardive dyskinesia. LIM persisted after withdrawal of levosulpiride in 48.1% of patients with LIP, 66.7% with dyskinesia, and none with isolated tremor. None of clinical and MRI features predicted the reversibility of LIP. Levosulpiride frequently causes drug‐induced movement disorders, presenting mainly with LIP followed by lower face dyskinesia. The symptoms are often severe, and irreversible even after the withdrawal of levosulpiride. Physicians should be cautious in using levosulpiride, especially in elderly patients. © 2009 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Hae‐Won Shin MD</name><affiliations><json:string>Parkinson/Alzheimer Center, Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea</json:string></affiliations></json:item><json:item><name>Mi J. Kim MD</name><affiliations><json:string>Parkinson/Alzheimer Center, Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea</json:string></affiliations></json:item><json:item><name>Jong S. Kim MD, PhD</name><affiliations><json:string>Parkinson/Alzheimer Center, Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea</json:string></affiliations></json:item><json:item><name>Myoung C. Lee MD</name><affiliations><json:string>Parkinson/Alzheimer Center, Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea</json:string></affiliations></json:item><json:item><name>Sun J. Chung MD, PhD</name><affiliations><json:string>Parkinson/Alzheimer Center, Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>levosulpiride</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>drug‐induced movement disorders</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinsonism</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dyskinesia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>tremor</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Levosulpiride is a substituted benzamide that is widely used for the management of dyspepsia and emesis. However, little is known about levosulpiride‐induced movement disorders (LIM). The aim of this study was to investigate the clinical characteristics of patients with LIM. Among 132 consecutive patients who were diagnosed with drug‐induced movement disorders between January 2002 and March 2008, 91 patients with LIM were identified and their medical records reviewed. Seventy‐eight (85.7%) patients were aged more than 60 years. The most common LIM was parkinsonism (LIP) (n = 85, 93.4%), followed by tardive dyskinesia (n = 9, 9.9%) and isolated tremor (n = 3, 3.3%). Twenty‐one (24.7%) of the 85 patients with LIP were rated as Hoehn and Yahr stage III–V. The oro‐lingual area was the only body part that was involved by tardive dyskinesia. LIM persisted after withdrawal of levosulpiride in 48.1% of patients with LIP, 66.7% with dyskinesia, and none with isolated tremor. None of clinical and MRI features predicted the reversibility of LIP. Levosulpiride frequently causes drug‐induced movement disorders, presenting mainly with LIP followed by lower face dyskinesia. The symptoms are often severe, and irreversible even after the withdrawal of levosulpiride. Physicians should be cautious in using levosulpiride, especially in elderly patients. © 2009 Movement Disorder Society</abstract><qualityIndicators><score>5.577</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1388</abstractCharCount><pdfWordCount>3081</pdfWordCount><pdfCharCount>20813</pdfCharCount><pdfPageCount>5</pdfPageCount><abstractWordCount>208</abstractWordCount></qualityIndicators><title>Levosulpiride‐induced movement disorders</title><genre><json:string>Serial article</json:string></genre><host><volume>24</volume><pages><total>5</total><last>2253</last><first>2249</first></pages><issn><json:string>0885-3185</json:string></issn><issue>15</issue><subject><json:item><value>Research Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2009</publicationDate><copyrightDate>2009</copyrightDate><doi><json:string>10.1002/mds.22805</json:string></doi><id>0E863B81DEB3FE5A3F083702B586A9FCC29E9D9C</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/0E863B81DEB3FE5A3F083702B586A9FCC29E9D9C/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/0E863B81DEB3FE5A3F083702B586A9FCC29E9D9C/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/0E863B81DEB3FE5A3F083702B586A9FCC29E9D9C/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Levosulpiride‐induced movement disorders</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2009</date></publicationStmt><notesStmt><note type="content">*Potential conflict of interest: Nothing to report.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Levosulpiride‐induced movement disorders</title><author><persName><forename type="first">Hae‐Won</forename><surname>Shin</surname><roleName type="degree">MD</roleName></persName><affiliation>Parkinson/Alzheimer Center, Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea</affiliation></author><author><persName><forename type="first">Mi J.</forename><surname>Kim</surname><roleName type="degree">MD</roleName></persName><affiliation>Parkinson/Alzheimer Center, Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea</affiliation></author><author><persName><forename type="first">Jong S.</forename><surname>Kim</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>Parkinson/Alzheimer Center, Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea</affiliation></author><author><persName><forename type="first">Myoung C.</forename><surname>Lee</surname><roleName type="degree">MD</roleName></persName><affiliation>Parkinson/Alzheimer Center, Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea</affiliation></author><author><persName><forename type="first">Sun J.</forename><surname>Chung</surname><roleName type="degree">MD, PhD</roleName></persName><note type="correspondence"><p>Correspondence: Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, 388‐1, Poongnap‐dong, Songpa‐gu, Seoul 138‐736, South Korea</p></note><affiliation>Parkinson/Alzheimer Center, Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-11-15"></date><biblScope unit="vol">24</biblScope><biblScope unit="issue">15</biblScope><biblScope unit="page" from="2249">2249</biblScope><biblScope unit="page" to="2253">2253</biblScope></imprint></monogr><idno type="istex">0E863B81DEB3FE5A3F083702B586A9FCC29E9D9C</idno><idno type="DOI">10.1002/mds.22805</idno><idno type="ArticleID">MDS22805</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2009</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Levosulpiride is a substituted benzamide that is widely used for the management of dyspepsia and emesis. However, little is known about levosulpiride‐induced movement disorders (LIM). The aim of this study was to investigate the clinical characteristics of patients with LIM. Among 132 consecutive patients who were diagnosed with drug‐induced movement disorders between January 2002 and March 2008, 91 patients with LIM were identified and their medical records reviewed. Seventy‐eight (85.7%) patients were aged more than 60 years. The most common LIM was parkinsonism (LIP) (n = 85, 93.4%), followed by tardive dyskinesia (n = 9, 9.9%) and isolated tremor (n = 3, 3.3%). Twenty‐one (24.7%) of the 85 patients with LIP were rated as Hoehn and Yahr stage III–V. The oro‐lingual area was the only body part that was involved by tardive dyskinesia. LIM persisted after withdrawal of levosulpiride in 48.1% of patients with LIP, 66.7% with dyskinesia, and none with isolated tremor. None of clinical and MRI features predicted the reversibility of LIP. Levosulpiride frequently causes drug‐induced movement disorders, presenting mainly with LIP followed by lower face dyskinesia. The symptoms are often severe, and irreversible even after the withdrawal of levosulpiride. Physicians should be cautious in using levosulpiride, especially in elderly patients. © 2009 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>levosulpiride</term></item><item><term>drug‐induced movement disorders</term></item><item><term>Parkinsonism</term></item><item><term>dyskinesia</term></item><item><term>tremor</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2009-04-24">Received</change><change when="2009-08-20">Registration</change><change when="2009-11-15">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/0E863B81DEB3FE5A3F083702B586A9FCC29E9D9C/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="150"><doi origin="wiley" registered="yes">10.1002/mds.v24:15</doi><numberingGroup><numbering type="journalVolume" number="24">24</numbering><numbering type="journalIssue">15</numbering></numberingGroup><coverDate startDate="2009-11-15">15 November 2009</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="100" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.22805</doi><idGroup><id type="unit" value="MDS22805"></id></idGroup><countGroup><count type="pageTotal" number="5"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2009 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2009-04-24"></event><event type="manuscriptRevised" date="2009-08-20"></event><event type="manuscriptAccepted" date="2009-08-20"></event><event type="publishedOnlineEarlyUnpaginated" date="2009-09-30"></event><event type="firstOnline" date="2009-09-30"></event><event type="publishedOnlineFinalForm" date="2009-11-19"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">2249</numbering><numbering type="pageLast">2253</numbering></numberingGroup><correspondenceTo>Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, 388‐1, Poongnap‐dong, Songpa‐gu, Seoul 138‐736, South Korea</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS22805.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="25"></count><count type="wordTotal" number="3984"></count></countGroup><titleGroup><title type="main" xml:lang="en">Levosulpiride‐induced movement disorders<link href="#fn2"></link></title><title type="short" xml:lang="en">Levosulpiride‐Induced Movement Disorders</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Hae‐Won</givenNames><familyName>Shin</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Mi J.</givenNames><familyName>Kim</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Jong S.</givenNames><familyName>Kim</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Myoung C.</givenNames><familyName>Lee</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Sun J.</givenNames><familyName>Chung</familyName><degrees>MD, PhD</degrees></personName><contactDetails><email>sjchung@amc.seoul.kr</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="KR" type="organization"><unparsedAffiliation>Parkinson/Alzheimer Center, Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">levosulpiride</keyword><keyword xml:id="kwd2">drug‐induced movement disorders</keyword><keyword xml:id="kwd3">Parkinsonism</keyword><keyword xml:id="kwd4">dyskinesia</keyword><keyword xml:id="kwd5">tremor</keyword></keywordGroup><supportingInformation><p> Additional Supporting Information may be found in the online version of this article. </p><supportingInfoItem><mediaResource alt="supporting information" href="urn-x:wiley:08853185:media:mds22805:MDS_22805_sm_SuppTable1"></mediaResource><caption>Supporting Information Table 1. Drugs causing drug‐induced movement disorders</caption></supportingInfoItem></supportingInformation><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Levosulpiride is a substituted benzamide that is widely used for the management of dyspepsia and emesis. However, little is known about levosulpiride‐induced movement disorders (LIM). The aim of this study was to investigate the clinical characteristics of patients with LIM. Among 132 consecutive patients who were diagnosed with drug‐induced movement disorders between January 2002 and March 2008, 91 patients with LIM were identified and their medical records reviewed. Seventy‐eight (85.7%) patients were aged more than 60 years. The most common LIM was parkinsonism (LIP) (n = 85, 93.4%), followed by tardive dyskinesia (n = 9, 9.9%) and isolated tremor (n = 3, 3.3%). Twenty‐one (24.7%) of the 85 patients with LIP were rated as Hoehn and Yahr stage III–V. The oro‐lingual area was the only body part that was involved by tardive dyskinesia. LIM persisted after withdrawal of levosulpiride in 48.1% of patients with LIP, 66.7% with dyskinesia, and none with isolated tremor. None of clinical and MRI features predicted the reversibility of LIP. Levosulpiride frequently causes drug‐induced movement disorders, presenting mainly with LIP followed by lower face dyskinesia. The symptoms are often severe, and irreversible even after the withdrawal of levosulpiride. Physicians should be cautious in using levosulpiride, especially in elderly patients. © 2009 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn2"><p>Potential conflict of interest: Nothing to report.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Levosulpiride‐induced movement disorders</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Levosulpiride‐Induced Movement Disorders</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Levosulpiride‐induced movement disorders</title></titleInfo><name type="personal"><namePart type="given">Hae‐Won</namePart><namePart type="family">Shin</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson/Alzheimer Center, Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Mi J.</namePart><namePart type="family">Kim</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson/Alzheimer Center, Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jong S.</namePart><namePart type="family">Kim</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Parkinson/Alzheimer Center, Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Myoung C.</namePart><namePart type="family">Lee</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson/Alzheimer Center, Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Sun J.</namePart><namePart type="family">Chung</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Parkinson/Alzheimer Center, Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea</affiliation><description>Correspondence: Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, 388‐1, Poongnap‐dong, Songpa‐gu, Seoul 138‐736, South Korea</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2009-11-15</dateIssued><dateCaptured encoding="w3cdtf">2009-04-24</dateCaptured><dateValid encoding="w3cdtf">2009-08-20</dateValid><copyrightDate encoding="w3cdtf">2009</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">2</extent><extent unit="references">25</extent><extent unit="words">3984</extent></physicalDescription><abstract lang="en">Levosulpiride is a substituted benzamide that is widely used for the management of dyspepsia and emesis. However, little is known about levosulpiride‐induced movement disorders (LIM). The aim of this study was to investigate the clinical characteristics of patients with LIM. Among 132 consecutive patients who were diagnosed with drug‐induced movement disorders between January 2002 and March 2008, 91 patients with LIM were identified and their medical records reviewed. Seventy‐eight (85.7%) patients were aged more than 60 years. The most common LIM was parkinsonism (LIP) (n = 85, 93.4%), followed by tardive dyskinesia (n = 9, 9.9%) and isolated tremor (n = 3, 3.3%). Twenty‐one (24.7%) of the 85 patients with LIP were rated as Hoehn and Yahr stage III–V. The oro‐lingual area was the only body part that was involved by tardive dyskinesia. LIM persisted after withdrawal of levosulpiride in 48.1% of patients with LIP, 66.7% with dyskinesia, and none with isolated tremor. None of clinical and MRI features predicted the reversibility of LIP. Levosulpiride frequently causes drug‐induced movement disorders, presenting mainly with LIP followed by lower face dyskinesia. The symptoms are often severe, and irreversible even after the withdrawal of levosulpiride. Physicians should be cautious in using levosulpiride, especially in elderly patients. © 2009 Movement Disorder Society</abstract><note type="content">*Potential conflict of interest: Nothing to report.</note><subject lang="en"><genre>Keywords</genre><topic>levosulpiride</topic><topic>drug‐induced movement disorders</topic><topic>Parkinsonism</topic><topic>dyskinesia</topic><topic>tremor</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><note type="content"> Additional Supporting Information may be found in the online version of this article.Supporting Info Item: Supporting Information Table 1. Drugs causing drug‐induced movement disorders - </note><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><detail type="issue"><caption>no.</caption><number>15</number></detail><extent unit="pages"><start>2249</start><end>2253</end><total>5</total></extent></part></relatedItem><identifier type="istex">0E863B81DEB3FE5A3F083702B586A9FCC29E9D9C</identifier><identifier type="DOI">10.1002/mds.22805</identifier><identifier type="ArticleID">MDS22805</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2009 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C86 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001C86 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:0E863B81DEB3FE5A3F083702B586A9FCC29E9D9C
|texte= Levosulpiride‐induced movement disorders
}}
| This area was generated with Dilib version V0.6.23. |  |